3C-Like-Proteinase Inhibitors Pipeline Insight Report 2021: A Cysteine Protease that is Excised from Polyproteins by its Own Proteolytic Activity and Forms a Homodimer with One Active Site Per Subunit – ResearchAndMarkets.comApril 8, 2021
DUBLIN–(BUSINESS WIRE)–The “3C-Like-Proteinase Inhibitors” report has been added to ResearchAndMarkets.com’s offering.
“3C-like-proteinase inhibitors – Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in 3C-like-proteinase inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
3C-like-proteinase inhibitors: Overview
3C-like-proteinase is a cysteine protease that is excised from polyproteins by its own proteolytic activity and forms a homodimer with one active site per subunit.
3CL pro reportedly recognizes the residues from P4 to P1 on the N-terminal side and P1′ on the C-terminal side of the cleavage sites, based on the consensus sequences around the processing sites in the SARS-CoV polyproteins and the extensive mutagenesis analyses of the N-terminal autoprocessing site. 3C-like proteases (3CLpros) from CoVs (also called main proteases) are essential for viral replication and are also involved in polyprotein cleavage and immune regulation, making them attractive and effective targets for the development of antiviral drugs.
3-chymotrypsin-like protease (3CL pro) is considered to be a promising drug target.
Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
The companies and academics are working to assess challenges and seek opportunities that could influence 3C-like-proteinase inhibitors R&D. The therapies under development are focused on novel approaches for 3C-like-proteinase inhibitors.
3C-like-proteinase inhibitors Emerging Drugs Chapters
This segment of the 3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
3C-like-proteinase inhibitors Emerging Drugs
Masitinib: AB Science
Masitinib is an orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, through inhibiting a limited number of kinases. Based on its unique mechanism of action, can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib is currently in late-stage development for ALS. Masitinib has received orphan drug designation for ALS from both the European Medicine Agency (EMA) and the U.S. Food and Drug Administration (FDA).
PF-07304814 is a small molecule that targets the 3CL protease, an enzyme that coronaviruses use to assemble themselves and multiply. PF-07304814 contains a phosphate group that makes the compound soluble and gets cleaved by alkaline phosphatase enzymes in tissue, releasing the active antiviral PF-00835231. The potential drug is in Phase I clinical studies for the treatment of COVID 2019 infections.
3C-like-proteinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different 3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on 3C-like-proteinase inhibitors
There are approx. 8+ key companies which are developing the 3C-like-proteinase inhibitors. The companies which have their 3C-like-proteinase inhibitors drug candidates in the most advanced stage, i.e. Phase III include, AB Science.
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
3C-like-proteinase inhibitors Report Insights
- 3C-like-proteinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
3C-like-proteinase inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Scenario and Emerging Therapies:
- How many companies are developing 3C-like-proteinase inhibitors drugs?
- How many 3C-like-proteinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for 3C-like-proteinase inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the 3C-like-proteinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for 3C-like-proteinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- AB Science
- Aligos Therapeutics
- Array BioPharma
- Eli Lilly and Company
- SOM Biotech
For more information about this report visit https://www.researchandmarkets.com/r/brspsf
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900